Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Mar 29;18(2):210–215. doi: 10.1111/tid.12510

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

PMC Copyright notice

Treatment patterns for respiratory syncytial virus infection in adult allogeneic and autologous hematopoietic stem cell transplant (HSCT), lung and non‐lung solid organ transplant (SOT), and hematologic (Heme) malignancy patients. Responses are from 11 centers; 10 centers responded with management in lung transplants. In some scenarios, individual centers treated patients with oral or inhaled ribavirin (RBV) depending on clinical circumstances, which is why the denominator exceeds 11 in certain scenarios. Intravenous immunoglobulin (IVIG) was used as monotherapy by 1 center in pre‐engraftment allogeneic and autologous HSCT patients with lower respiratory tract infection (LRTI), post‐engraftment allogeneic and autologous HSCT patients with LRTI within 3 months of transplant, and in patients with graft‐versus‐host disease (GVHD) and LRTI. IVIG was otherwise given in combination with oral or inhaled RBV. URTI, upper respiratory tract infection; rx, treatment.